New test spots TB drug resistance weeks sooner

Tuberculosis remains a global challenge in part because determining which drugs will kill a patient’s Mycobacterium tuberculosis strain can take weeks. In conventional approaches, investigators wait for bacteria to grow enough to measure colony forming units, a slow process that delays treatment choices. To address that delay, researchers led by corresponding author L. Schwartz created a new laboratory assay called Tre-DST that uses solvatochromic trehalose probes to report bacterial activity. In tests described in the abstract, Tre-DST was able to show CFU/mL to become detectable, over two weeks earlier than colony forming unit analysis. By detecting metabolic or cell-wall changes with a fluorescent readout, the new approach aims to reveal whether a drug is working without waiting for colonies to form. The abstract presents this advance as a faster way to observe whether Mycobacterium tuberculosis is alive and responding to drugs, framing Tre-DST as a potential diagnostic tool for reference laboratories that need quicker drug susceptibility information.

The core of Tre-DST is its solvatochromic trehalose probes, which produce fluorescence linked to bacterial processes. The abstract reports that Tre-DST measures loss of fluorescence when Mycobacterium tuberculosis strains are exposed to frontline and newer drugs, demonstrating drug-agnostic reporting of susceptibility. Specifically, the assay showed loss of fluorescence with rifampicin (RIF), isoniazid (INH), and ethambutol, as well as the newer drug bedaquiline. Tre-DST also distinguished RIF- and INH-resistant auxotrophs from susceptible controls and accurately reported resistance activity. Those results indicate that rather than depending on a particular resistance mechanism, the test senses whether the organism itself is affected by the drug. The abstract contrasts this rapid fluorescent readout with slower colony-based measures and suggests Tre-DST can give actionable information about susceptibility by observing changes in fluorescence instead of waiting for colony growth.

The implications described in the abstract center on speed and broad applicability. Because Tre-DST is agnostic to mechanisms of drug resistance, the authors suggest the assay is likely compatible with all WHO-recommended DR-TB drugs as well as any future TB drugs as a diagnostic in reference laboratories. Faster readouts — more than two weeks earlier than colony forming unit analysis — could shrink the time needed to identify effective treatments in a laboratory setting. Being drug-agnostic means laboratories would not need separate molecular tests for every resistance gene or mechanism; instead, Tre-DST would report whether a drug is having its intended effect on Mycobacterium tuberculosis. The abstract positions Tre-DST as a potentially practical diagnostic addition for reference labs tasked with testing a broad panel of drugs, including both established treatments and new agents, without requiring mechanism-specific assays.